Caike Biotechnology
Advanced life science tools for high-resolution data
About Caike Biotechnology
Caike (Suzhou) Biotechnology Co., Ltd. is a life sciences company that develops and produces advanced research tools and instruments. Founded in 2018 in the Suzhou BioBay by several PhDs returning from the United States, the firm focuses on providing high-resolution data for life science researchers. The company's core technology, μ-MPF (Micro-scaled Multi-Physics coupled Force), underpins its product line, which includes a high-throughput single-cell photoconductive system and a single-molecule immunoassay analyzer. These products are designed to enhance research at the single-cell and single-molecule levels, enabling highly sensitive detection of biomarkers and functional screening.
Caike Biotechnology's business model is centered on developing and commercializing its proprietary platform technology and associated products, including instruments and reagents, for the life sciences and in-vitro diagnostics markets. The company serves researchers and clinicians, providing tools for applications such as the development and validation of low-abundance biomarkers, bioanalysis in drug development, and early disease detection and prognosis. For example, their single-molecule immunoassay system can directly analyze biomarkers in serum, plasma, and other biological fluids with ultra-high sensitivity.
Since its inception, Caike Biotechnology has achieved significant milestones and secured substantial funding. The company received an angel round investment in 2020 from IDG Capital and Borui Bio-medicine. This was followed in 2021 by Series A-1 and A-2 financing rounds, co-led by IDG Capital, Langyu Capital, and PerkinElmer Ventures, and a 150 million yuan Series B round co-led by Legend Capital, Hillhouse Capital, and CMG-SDIC Capital. In 2022, the company's single-molecule equipment received NMPA approval for IVD use, and its single-cell products were officially launched. The firm has also established a marketing center in Shanghai and an application technology center to support customer-driven R&D.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 12.4/100
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2021 | $21M | $83M | Legend Capital · SDIC China Merchants · IDG Capital · Honghui China | ↗ |
Growth signals
Latest recorded traffic for Caike Biotechnology is 960 monthly website visits, up 39.1% over the last three months.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Legend Capital- SMSDIC China Merchants
IDG Capital- HCHonghui China
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Caike Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Caike Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.